Precision Optimization of Behavioral Activation for Major and Subthreshold Depression: A Meta-Analysis of Exploring Dose-Response Relationships and Moderating Factors.

J Am Acad Child Adolesc PsychiatryJan 5, 2026 (epub)
Clinical ResearchPsychiatry

Xiaolong Huang, Wei Luo, Jiacheng Luo et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis of randomized controlled trials assessed behavioral activation (BA) for adolescents with subthreshold depression or major depressive disorder. Fourteen studies were included, with 11 trials and 572 participants contributing to meta-analysis. Compared with treatment as usual, BA reduced depressive symptoms with a moderate effect (SMD = -0.42); the effect was larger versus no-treatment controls (SMD = -0.87). Effects were greater for mild than severe symptoms, and the authors concluded that short-term, school-based BA may benefit older adolescents with mild depressive symptoms.

Key findings

  • BA showed a moderate effect versus treatment-as-usual (SMD = -0.42) and a large effect versus no-treatment controls (SMD = -0.87).
  • Effects were larger for mild depressive symptoms (SMD = -0.93) than severe symptoms (SMD = -0.43).
  • BA without parental involvement had larger effects than BA with parental participation (SMD = -0.94 vs -0.38; p < .0001), though the comparison may be confounded.
  • BA moderately improved behavioral activation levels and functioning (SMD = 0.49).

Why it matters

The findings suggest BA may be a useful intervention option for adolescent depression, with stronger symptom effects in milder presentations. The results also indicate that setting and participant characteristics may influence outcomes, underscoring the importance of matching implementation to the population and interpreting subgroup comparisons cautiously.

What to keep in mind

The meta-analysis included 11 trials and 572 participants; the authors call for larger samples, standardized follow-up assessments, and more representative samples. The apparent effect of parental involvement may be confounded by age, symptom severity, and setting.

Source

Published in J Am Acad Child Adolesc Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.